

CD19,CD274,CD3E,TNFRSF9 Research Grade Emfizatamab

Catalog No.	DHD10809A DHD10809B	Quantity:	100 µg 1.0 mg
Alternate Names:	GNC 038, GNC-038, GNC038, CAS: 2559704-23-1		
Description:	Research Grade Emfizatamab is a tetra-specific humanized monoclonal antibody that targets human B-lymphocyte antigen CD19, Programmed cell death 1 ligand 1 (PD-L1), T-cell surface glycoprotein CD3 epsilon chain (CD3e) and Tumor necrosis factor receptor superfamily member 9 (CD137)		
UniProt ID (target):	P15391 & Q9NZQ7 & P07766 & Q07011		
Specificity:	Human CD19, PD-L1, CD3e, and CD137		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO cell line		
Isotype:	Tetra-specific humanized (scFv-kappa-heavy)-G1_L-kappa-(scFv-heavy-kappa)-(scFv-heavy-kappa)		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
Applications:	Functional studies		
INN:	Emfizatamab		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.